Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.

Period	Debt/Equity
2017-12-31	0.05
2018-12-31	0.06
2019-12-31	0.10
2020-12-31	0.12
2021-12-31	0.16
2022-12-31	0.45
2023-12-31	0.96
2024-12-31	1.38

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RYTM	$85.48	+0.00%	0.98M
3
4
5

Rhythm Pharmaceuticals Inc. (RYTM) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Rhythm Pharmaceuticals Inc. Data in Excel

More RYTM Financial Data